A. Mullard

发表

Checklists for Complications During Systemic Cancer Treatment Shared by Patients, Friends, and Health Care Professionals: Prospective Interventional Cohort Study

C. Subbe, H. Jones, Harry Smith, 2020, JMIR mHealth and uHealth.

A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).

A. Mullard, S. Gollins, J. Morris, 2018, Clinical oncology (Royal College of Radiologists (Great Britain)).

Reducing febrile neutropenia rates in early breast cancer. Experience of two UK cancer centres

A. Mullard, V. Misra, S. O'Reilly, 2014, Supportive Care in Cancer.

The detection of germline and somatic BRCA1/2 genetic variants through parallel testing of patients with high‐grade serous ovarian cancer: a national retrospective audit

A. Mullard, E. Hudson, S. Morgan, 2021, BJOG : an international journal of obstetrics and gynaecology.

A review of systemic anticancer therapy in disease palliation

A. Mullard, C. Usborne, 2018, British medical bulletin.

Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up

A. Mullard, Trevor Jones, A. Finall, 2022, Journal of Clinical Pathology.

Checklists for Complications During Systemic Cancer Treatment Shared by Patients, Friends, and Health Care Professionals: Prospective Interventional Cohort Study (Preprint)

C. Subbe, H. Jones, Harry Smith, 2020 .

Intractable malignant ascites: an alternative management option.

A. Mullard, M. Jibani, J. M. Bishop, 2011, Journal of palliative medicine.

Venous thromboembolism in malignancy.

A. Mullard, H. Innes, 2014, Clinical medicine.

Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.

K. Dwan, A. Mullard, M. Richardson, 2015, Health technology assessment.

Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.

V. Goh, T. Powles, M. Highley, 2023, The Lancet. Oncology.

Evaluating process and effectiveness of a low-intensity CBT intervention for women with gynaecological cancer (the EPELIT Trial)

A. Mullard, N. Hulbert-Williams, A. Price, 2021, AMRC Open Research.

Checklists for Complications During Systemic Cancer Treatment Shared by Patients, Friends, and Health Care Professionals: Prospective Interventional Cohort Study

C. Subbe, H. Jones, Harry Smith, 2020, JMIR mHealth and uHealth.

Checklists for Complications During Systemic Cancer Treatment Shared by Patients, Friends, and Health Care Professionals: Prospective Interventional Cohort Study (Preprint)

C. Subbe, H. Jones, Harry Smith, 2020 .

Radical hypofractionated radiotherapy for the treatment of non-small-cell lung cancer using 52·5–55 Gy in 20 fractions: the North Wales Cancer Centre experience

A. Mullard, N. Ghosal, C. Fuller, 2015 .